// OVERVIEW
End-to-end AI platform for drug development, from drug discovery to clinical trial design, using AI agents tuned to different data types.
Discussed in
// RECENT MENTIONS
// SIGNALS
7 SIGNALS
01
mention·Axios Pro Rata·JUNE 11, 2026
“Kardigan set IPO terms targeting a $1.6B fully diluted value; backed by Arch Venture Partners, Perceptive, Fidelity, T. Rowe Price, and Sequoia Heritage.”
02
funding·T1 Scout·JUNE 1, 2026
Source→03
funding·T1 Scout·MAY 31, 2026
Source→AI-extracted from podcast / newsletter / paper summaries. May contain errors.